United Therapeutics (NASDAQ:UTHR) CEO Sells $5,167,715.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the business’s stock in a transaction dated Friday, June 26th. The stock was sold at an average price of $543.97, for a total value of $5,167,715.00. Following the completion of the transaction, the chief executive officer directly owned 40,513 shares of the company’s stock, valued at approximately $22,037,856.61. This trade represents a 19.00% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

United Therapeutics Stock Up 0.4%

Shares of NASDAQ UTHR traded up $2.26 during trading on Monday, reaching $544.92. 412,282 shares of the company traded hands, compared to its average volume of 498,599. The firm has a 50 day simple moving average of $561.23 and a 200-day simple moving average of $525.91. The stock has a market capitalization of $23.13 billion, a PE ratio of 20.12, a P/E/G ratio of 1.79 and a beta of 0.57. United Therapeutics Corporation has a 52-week low of $272.12 and a 52-week high of $609.35.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The company had revenue of $781.50 million for the quarter, compared to the consensus estimate of $797.40 million. During the same quarter last year, the company earned $6.63 EPS. The firm’s revenue for the quarter was down 1.6% on a year-over-year basis. As a group, research analysts predict that United Therapeutics Corporation will post 26.49 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on UTHR. Jefferies Financial Group reissued a “buy” rating on shares of United Therapeutics in a report on Monday, March 2nd. Wells Fargo & Company upgraded shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their target price for the company from $575.00 to $735.00 in a research report on Thursday, May 7th. Bank of America boosted their price objective on shares of United Therapeutics from $569.00 to $626.00 and gave the company a “neutral” rating in a research report on Tuesday, March 31st. Raymond James Financial assumed coverage on United Therapeutics in a research note on Friday, April 10th. They issued an “outperform” rating and a $700.00 price objective for the company. Finally, Morgan Stanley set a $516.00 target price on United Therapeutics in a report on Thursday, May 7th. Eleven analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $619.42.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Arjuna Capital grew its holdings in United Therapeutics by 2.8% during the 1st quarter. Arjuna Capital now owns 662 shares of the biotechnology company’s stock valued at $393,000 after buying an additional 18 shares in the last quarter. Clearstead Advisors LLC lifted its stake in United Therapeutics by 8.9% in the 3rd quarter. Clearstead Advisors LLC now owns 280 shares of the biotechnology company’s stock worth $117,000 after purchasing an additional 23 shares in the last quarter. Sage Rhino Capital LLC boosted its holdings in shares of United Therapeutics by 5.1% during the 1st quarter. Sage Rhino Capital LLC now owns 474 shares of the biotechnology company’s stock valued at $281,000 after purchasing an additional 23 shares during the last quarter. Bryn Mawr Trust Advisors LLC increased its holdings in shares of United Therapeutics by 5.4% in the first quarter. Bryn Mawr Trust Advisors LLC now owns 465 shares of the biotechnology company’s stock worth $276,000 after purchasing an additional 24 shares during the last quarter. Finally, Meeder Advisory Services Inc. increased its holdings in shares of United Therapeutics by 4.1% in the first quarter. Meeder Advisory Services Inc. now owns 661 shares of the biotechnology company’s stock worth $392,000 after purchasing an additional 26 shares during the last quarter. 94.08% of the stock is owned by hedge funds and other institutional investors.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.